(1990). Appendicular bone density and age predict hip fracture in women. The Study of Osteoporotic Fractures Research Group. JAMA
(1999). Calcitriol and alendronate combination treatment in menopausal women with low bone mass.
(1989). Chesnut CH: Calcitriol treatment is not effective in postmenopausal osteoporosis.
(2002). Curative effect of combined treatment with alendronate and 1 alpha-hydroxyvitamin D3 on bone loss by ovariectomy in aged rats.
(1995). Eisman JA: Vitamin D receptor genotypes and bone mineral density. Lancet
(1994). Ekeland A: Fracture strength prediction in rat femoral shaft and neck by single photon absorptiometry of the femoral shaft. Bone Miner
(1996). Ensrud KE: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet
(1990). GA: Aminohydroxybutane bisphosphonate inhibits bone loss due to immobilization in rats.
(2000). GA: Bone mineral density and bone structure parameters as predictors of bone strength: an analysis using computerized microtomography and gastrectomy-induced osteopenia in the rat.
(1993). Genant HK: Simple measurement of femoral geometry predicts hip fracture: the study of osteoporotic fractures.
(2003). Hip fractures among the elderly: causes, consequences and control. Ageing Res Rev
(1987). I: Postmenopausal osteoporosis: no effect of three years treatment with 1,25-dihydroxycholecalciferol. Acta Med Scand
(1985). Ignaszewski LA: Skeletal alterations in ovariectomized rats. Calcif Tissue Int
(1996). JP: Bone density and shape as determinants of bone strength in IGF-I and/or pamidronate-treated ovariectomized rats. Osteoporos Int
(1998). Komoriya K: Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: comparison with pamidronate and etidronate in growing rats. J Pharmacol Exp Ther
(1992). LJ: Hip fractures in the elderly: a world-wide projection. Osteoporos Int
(1998). Marcolongo R: Effects of combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis: two years of continuous treatment. Clin Drug Invest
(1998). Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol
(2002). Mohan S: Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone
(2004). Nowinska B: Effect of administration of alendronate sodium and retinol on the mechanical properties of the femur in ovariectomized rats.
(2000). Ogata E: Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct actions from estrogen. J Bone Miner Res
(2003). Omura K: Administration of parathyroid hormone, prostaglandin E2, or 1-alpha, 25-dihydroxyvitamin D3 restores the bone inductive activity of rhBMP-2 in aged rats.